Page 54 - Read Online

146. Lee C, He H, Jiang Y, Di Y, Yang F, Li J, Jin C, Fu D. Elevated clinical outcome following adjuvant therapy in resectable
expression of tumor miR-222 in pancreatic cancer is associated pancreatic cancer. PLoS One 2010;5:e10630.
with Ki67 and poor prognosis. Med Oncol 2013;30:700. 150. Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting
147. Zhu Z, Xu Y, Du J, Tan J, Jiao H. Expression of miR-21 for the therapy of pancreatic cancer. Mol Ther
microRNA-218 in human pancreatic ductal adenocarcinoma 2013;21:986-94.
and its correlation with tumor progression and patient survival. 151. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D,
J Surg Oncol 2014;109:89-94. Desano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS,
148. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Xu L. MicroRNA miR-34 inhibits human pancreatic cancer
Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, tumor-initiating cells. PLoS One 2009;4:e6816.
Danesi R, Campani D, Verheul HM, Boggi U. MicroRNA-21 152. Weiss FU, Marques IJ, Woltering JM, Vlecken DH,
in pancreatic cancer: Correlation with clinical outcome and Aghdassi A, Partecke LI, Heidecke CD, Lerch MM,
pharmacologic aspects underlying its role in the modulation of Bagowski CP. Retinoic acid receptor antagonists inhibit
gemcitabine activity. Cancer Res 2010;70:4528-38. miR-10a expression and block metastatic behavior of
149. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, pancreatic cancer. Gastroenterology 2009;137:2136-45.e1-7.
Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, 153. Li Y, Vandenboom TG 2nd, Wang Z, Kong D, Ali S, Philip PA,
Kim SW, Del Chiaro M, Peters GJ, Giaccone G. Identifi cation Sarkar FH. miR-146a suppresses invasion of pancreatic cancer
of microRNA-21 as a biomarker for chemoresistance and cells. Cancer Res 2010;70:1486-95.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦ 155